Twenty-Four-Hour Effectiveness of BMS 180048 in the Acute Treatment of Migraine Headaches

Authors


  • A complete list of the participants in this research study appears at the end of this article.

  • Presented at the 38th Annual Scientific Meeting of the American Association for the Study of Headache, San Diego, Calif, May 31, 1996.

Dr. Robert E. Ryan, Jr, Ryan Headache Center, 621 South New Ballas Road, St.Louis, MO 63141.

Abstract

The efficacy of BMS 180048, a 5HT, agonist in the acute treatment of a migraine headache, was evaluated in 216 patients. Three doses of the study drug were compared to placebo. Patients received a single test dose in the physician’s office while being evaluated with a Holter monitor during a headache-free day. They then treated a migraine headache with a single dose of the study drug as an outpatient. The 150 mg and 200mg doses of BMS were significantly superior to placebo on change in pain intensity at 2 hours. Patients treated with BMS 180048 had a longer duration of response than placebo-treated patients. At the 24hour point, only 24% of the 150mg group and 25% of the 200mg group had relapsed, compared to placebo which had a 42% relapse rate. It is concluded that BMS 180048 is an effective compound for the treatment of migraine headaches with a prolonged duration of response.

Ancillary